Pet Biologics Enter the Industrialization Window

Table of Content [Hide]

Pet healthcare is shifting from a consumption-driven model to a technology-driven one. In the past, the core logic of the pet pharmaceutical market centered on “basic immunization + routine treatment.” Today, however, more and more companies are turning their attention to a field with higher technical barriers and greater long-term value: pet biologics.

From vaccines to recombinant proteins, and now to pet monoclonal antibodies that are rapidly coming into focus, pet biologics are no longer just a “new concept.” They have become a validated industrial opportunity across products, capital, and manufacturing. What truly defines the value of this sector is not merely incremental market growth, but the new demands it brings for process platforms, the technical challenges it introduces, and the emerging opportunities for domestic substitution.

Pet Biologics: Key Incremental Products

Compared with traditional pharmaceuticals, the value of biologics in pet healthcare is becoming increasingly clear, mainly for three reasons:

Targeted with high added value
Well suited for chronic diseases and long-term management
Easier to establish differentiated therapeutic positioning

This category not only includes more established pet vaccines, but also rapidly emerging recombinant proteins and pet monoclonal antibodies. From a manufacturing perspective, it represents one of the most demanding areas in terms of platform capabilities. Although pet monoclonal antibodies are classified as veterinary drugs in terms of product positioning, their manufacturing logic is increasingly resembling a cost-optimized version of human biologics.

They must meet strict requirements for:

Activity and consistency
Safety
Control of immunogenicity risks
Impurity control

At the same time, they face more practical industry constraints:

Lower payment ceiling in the pet market
Higher price sensitivity in commercialization
Strong pressure to control production costs

As a result, real competition in this field will not be limited to molecular design. It will increasingly take place in areas such as:

Cell line development efficiency
Upstream culture productivity
Downstream recovery yield
Resin lifetime
Single-use system strategies
End-to-end COGS optimization capabilities

Process Characteristics of Pet Biologics

Similar to human biologics, but not identical

Pet biologics leverage many established platforms from human biologics. However, during real industrialization, they exhibit several distinct process characteristics:

1. Higher cost sensitivity, process design must start from a "commercialization" perspective

2. Stronger demand for platformized processes, with greater need for “replicable process packages”

This means that in the future, pet biologics companies will show a stronger preference for:

Standardized upstream platforms
Modular downstream platforms
Single-use processing systems
Prepacked resins and pre-validated consumables
Filtration and chromatography solutions that are easier to scale up

3. The process route requires a balance between "performance" and "cost" to achieve: "Stable and scalable target quality at an acceptable cost."

figure-1-platform-based-process-for-feline-trivalent-vaccine.jpg

Figure 1: Platform-Based Process for Feline Trivalent Vaccine

The real challenge of pet biologics lies not in

“making it work in the lab,”

but in “making it stable at a commercial scale.”

This brings several typical challenges:

1. Rapid establishment of process platforms

2. Stable and scalable manufacturing processes

3. Delivering products under controlled cost constraints

In the future, many pet biopharmaceutical companies will not build "human-drug-level heavy-asset large platforms" from the very beginning. Instead, they are more likely to move toward:

Medium-scale operations
Multi-product switching
Platform reuse
Single-use–first strategies
Fast time-to-market orientation

This means that, on the manufacturing side, increasing emphasis will be placed on:

Single-use bioreactors
TFF/UFDF platforms
Modular chromatography systems
Prepacked columns and prefilled resins
Flexible production solutions for small-batch, multi-batch manufacturing

figures-2-platform-based-process-workflow-solutions.jpg

figures-3-platform-based-process-workflow-solutions.jpg

figures-4-platform-based-process-workflow-solutions.jpg

Figures 2, 3, and 4: Platform-Based Process Workflow Solutions

Summary

Pet biologics are becoming one of the most noteworthy directions in the animal health industry. From today’s perspective, pet biologics should not be viewed merely as “a new market,” but rather as an emerging biomanufacturing paradigm in the making.

References

Popular Bioprocessing Products

Puredex<sup>®</sup> LH-20 Resin for Size Exclusion Chromatography

Puredex^® LH-20 Resin for Size Exclusion Chromatography

Chromstar<sup>®</sup> BB Resins for Ion Exchange Chromatography

Chromstar^® BB Resins for Ion Exchange Chromatography

Maxgo^® 15/30RPC

Link With Us Now!

Want to know more about BioLink bioprocessing products? Feel free to contact BioLink now!

Email

info@biolink.com

Phone

0086-400-058-9000

ADDRESS

From Selection to Application: Technical Matching Analysis of Agitators with Fluids of Different Viscosities

23 Mar 2025